Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 2
1948 6
1949 4
1950 1
1951 4
1954 3
1958 1
1959 2
1961 2
1962 1
1964 2
2005 1
2011 1
2012 2
2013 4
2014 6
2015 4
2016 9
2017 7
2018 12
2019 17
2020 42
2021 32
2022 30
2023 21
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Novel targets for immune-checkpoint inhibition in cancer.
Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A, Friedlaender A. Borgeaud M, et al. Among authors: friedlaender a. Cancer Treat Rev. 2023 Nov;120:102614. doi: 10.1016/j.ctrv.2023.102614. Epub 2023 Aug 12. Cancer Treat Rev. 2023. PMID: 37603905 Free article. Review.
Drugging KRAS: current perspectives and state-of-art review.
Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo A. Parikh K, et al. Among authors: friedlaender a. J Hematol Oncol. 2022 Oct 25;15(1):152. doi: 10.1186/s13045-022-01375-4. J Hematol Oncol. 2022. PMID: 36284306 Free PMC article. Review.
A BRAF new world.
Frisone D, Friedlaender A, Malapelle U, Banna G, Addeo A. Frisone D, et al. Among authors: friedlaender a. Crit Rev Oncol Hematol. 2020 Aug;152:103008. doi: 10.1016/j.critrevonc.2020.103008. Epub 2020 May 26. Crit Rev Oncol Hematol. 2020. PMID: 32485528 Review.
Neoadjuvant Immunotherapy: A Promising New Standard of Care.
Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A. Boydell E, et al. Among authors: friedlaender a. Int J Mol Sci. 2023 Jul 24;24(14):11849. doi: 10.3390/ijms241411849. Int J Mol Sci. 2023. PMID: 37511609 Free PMC article. Review.
Antibody Drug Conjugates in Lung Cancer.
Merle G, Friedlaender A, Desai A, Addeo A. Merle G, et al. Among authors: friedlaender a. Cancer J. 2022 Nov-Dec 01;28(6):429-435. doi: 10.1097/PPO.0000000000000630. Cancer J. 2022. PMID: 36383905 Review.
Pleural Mesothelioma in the Era of Immunotherapy.
Chevallier M, Kim F, Friedlaender A, Addeo A. Chevallier M, et al. Among authors: friedlaender a. Clin Med Insights Oncol. 2023 Jul 20;17:11795549231178173. doi: 10.1177/11795549231178173. eCollection 2023. Clin Med Insights Oncol. 2023. PMID: 37492425 Free PMC article. Review.
First-line immunotherapy in non-small cell lung cancer: how to select and where to go.
Mogavero A, Cantale O, Mollica V, Anpalakhan S, Addeo A, Mountzios G, Friedlaender A, Kanesvaran R, Novello S, Banna GL. Mogavero A, et al. Among authors: friedlaender a. Expert Rev Respir Med. 2023 Dec;17(12):1191-1206. doi: 10.1080/17476348.2024.2302356. Epub 2024 Feb 9. Expert Rev Respir Med. 2023. PMID: 38294292 Review.
212 results